Testing your cancer genes will help in detecting hereditary cancer diseases early in order to find certainty, identify risks, and start timely treatment.
With myLifeCancer™, we sequence your entire genomic DNA and analyse more than 1300 genes related to cancer. After every analysis, you will receive a detailed report with further information and action points. myLifeCancer™ also includes a subscription to quarterly updates of your results based on most recent scientific knowledge.
Quarterly updates of your genomic results based on the most recent scientific knowledge.
With your consent we report previously unknown genomic results in specific genes that have a treatment consequence but are not related to your potential clinical symptoms.
Results and recommendations are presented in a suitable way for non-medical people and more in-depth for genomic experts.
Past and current strategies have relied on environmental factors that contribute to cancer diseases. However, the crucial role of genomics has become more and more evident recently.
There are numerous cancers that are caused by mutations, also called pathogenic variants, in more than 1300 genes.
5% – 10% of breast cancer cases and 10% – 15% of ovarian cancer cases are hereditary. Most cases of hereditary breast and ovarian are caused by pathogenic variants in BRCA1 and BRCA2.
However, the main problem is that most of the diseases do not show any symptoms and signs until it is too late, and, in many cases, the diagnosis takes too long.
Genomic testing is the only reliable method of diagnosing and confirming genetically based cancers, partially even before the appearance of any symptoms and signs. This early diagnosis is critical with diseases where the first symptoms are already life-threatening or fatal.
With genomic testing, customers can select optimal methods of treatment such as specific medicine or surgical intervention.
Additionally, potentially affected relatives can be warned and can use genomic testing to detect potential disorders and take preventive measures themselves.
The Arcensus Direct-to-Consumer ‘Genomic-testing-first’ approach allows us to
Arcensus myLifeCancer™ genomic testing offers the optimal package based on the complete analysis of more than 1300 genes.
Today only about 1% of all known mutations can be interpreted correctly and with the highest quality. However, genomics is rapidly evolving with the growing potential to interpret more and more mutations in the future.
This increase in better scientific interpretation of mutations will make it possible to continuously improve the world’s knowledge in describing the clinical consequences of given genomic mutations.
With your subscription to Arcensus’s services, we will send you an updated report based on newly discovered scientific data and updated interpretation of genomic mutations every three months. This way, your genomic data is continuously checked with the latest clinical research and stays up-to-date in a rapidly evolving medical field.
You can also see our instruction manual for further information.